This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain patent-term extensions for drugs, pesticides or agricultural chemicals, a careful…
Posts published in “Insights”
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch can help you replace or supplement your current solutions with:…
Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at Bentley University published a paper investigating the involvement of government…
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means fewer generic entrants and less opportunities for consumers to enjoy…
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A. van Bodegraven, Nanne K.H. de Boer, and Chris J.J. Mulder in Drug Discovery Today under a Creative Commons…
When drug patents expire, billions of dollars in revenues can disappear overnight as competitors enter the market. Accordingly, many investors focus on drug patents when evaluating drug companies. But, there…
Just because a drug has received FDA approval does not mean that it is available in the marketplace. But, why would a company go through all the trouble and expense…
The USPTO Office of the Chief Economist has releases a comprehensive set of patent litigation data files for public use. The Patent Litigation Dataset has been updated as of December…
The FDA Orange Book, or Approved Drug Products with Therapeutic Equivalence Evaluations, is the definitive source to link drugs with the patents that protect them. Over the years we’ve had…
This article was originally published by Syed Sauban Ghani in Eclética Química under a Creative Commons license. ABSTRACT As scientific community worldwide is publishing a huge number of research articles…
